Facilitated By

San Antonio Medical Foundation

Phase II Trial of Combination Immunotherapy with nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in high-risk HER2+ Breast Cancer Patients (2014-0443)

Cancer Insight, LLC

Cancer Insight is a Texas-based boutique contract research organization (CRO) dedicated to discovering, developing and testing emerging biotechnologies focused on cancer immunotherapy. Founded by industry pioneer Dr.

Principal Investigator(s)
George Peoples
Funded by
Industry Sponsored
Research Start Date

The goal of this trial is to compare if and for how long trastuzumab combined with either NeuVax (nelipepimut-S given with GM-CSF [sargramostim]) or sargramostim can help control the disease in patients with HER2 positive breast cancer. NeuVax is not FDA approved or commercially available. It is currently being used for research purposes only. Sargramostim is FDA approved and commercially available to help raise patients’ white blood cell counts after chemotherapy. Giving NeuVax or sargramostim to patients with HER2-positive breast cancer is investigational. Trastuzumab is FDA approved and commercially available to treat HER2-positive breast cancer.

Drug Discovery